Talking Precision Medicine

Our guest this episode is Charles Fisher, co-founder and currently Chief Scientific Officer of Unlearn.AI. Unlearn has been a leader in the advancement of Digital Twins as a tool to drastically improve the efficiency of clinical trials. Not only a visionary scientist and trailblazing entrepreneur, Charles is fearless with his hot takes. So sit back and enjoy this free wheeling conversation!

Episode 40 links:

What a genuine pleasure to sit with Thierry Bernard, CEO of Qiagen. As I told Thierry, Qiagen is a truly iconic brand for anyone who came up through molecular biology laboratories in the past 30 years. Their products were ubiquitous, and crucial, to the success of our research. In this conversation, Thierry talks about his global vision for precision medicine, and his mantra that we leave no patient behind.

Episode 39 links:

What a pleasure to sit down with my long time colleague and friend, Art Krieg, to discuss his latest venture, Zola Therapeutics, and his adventures in the great outdoors. Art has launched and exited a number of innovative biotechs, each time delving deeper into mechanisms by which we can harness the immune system for therapeutic purposes. Join us as we discuss how — despite a well earned retirement — the siren song that led to Zola was strong enough to get Art back in the game. 

Episode 38 links:

In this episode I chat with Dr Sarah Hein, co-founder and CEO of March Biosciences, a Houston Based biotech developing cell therapies for T-cell malignancies. Sarah is an old friend and colleague from our days as trainees at Baylor College of Medicine, where we both circulated among those with ambitions of entrepreneurship. Sarah has definitely made good in that regard, as a serial entrepreneur deeply enmeshed in Houston’s growing life sciences and healthtech ecosystem.

Episode 37 links:

This episode features two guests, Jennifer Goldsack and Yashoda Sharma, of the Digital Medicine Society, or DiMe. We’re going to get into the nitty gritty of healthcare disparities in terms of access and outcomes, and how digital solutions are a big part of the overall solution. 

Episode 36 links:

In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies.

Episode 35 links:

Today we turn the mic around, as our guest Adam Stasio hosts an excellent podcast of his own. Adam’s day job, however, is running SciMed, a boutique life sciences software development company. Adam and Genialis CEO Rafael Rosengarten discuss the state of scientific software, the importance of agility and communication, and approaches to building a lasting company culture.

Visit ⁠⁠TPM E34⁠⁠ for highlights and links from this episode.

Our guest today is Dr. Ashley Zehnder, co-founder and CEO of Fauna Bio. Fauna is a revolutionary young biotech company using comparative genomics of an array of non-traditional mammalian models to discover new therapeutic opportunities for people. What do ground squirrels have to do with treating battlefield trauma? Only one way to find out …

Visit ⁠TPM E33⁠ for highlights and links from this episode.

In this episode, Genialis CEO Rafael Rosengarten sits down with Ajay Gopal, CEO and founder of Rx Studio. Rx Studio is a technology company using data science to tackle a major limitation to personalized medicine: drug dosing.

Visit TPM E32 for highlights and links from this episode.

In this episode, Genialis CEO Rafael Rosengarten speaks with BCG management consultant and healthcare innovation expert Amy MacDougall. They discuss emerging trends in healthcare, the role of AI, ethics and more, as well as BCG’s recently released 50 Most Innovative Companies List.

Visit TPM E31 for highlights and links from this episode.